Genotype/phenotype correlation of the G85E mutation in a large cohort of cystic fibrosis patients

被引:20
作者
Decaestecker, K
Decaestecker, E
Castellani, C
Jaspers, M
Cuppens, H
De Boeck, K
机构
[1] Catholic Univ Louvain, Cyst Fibrosis Ctr Leuven, Dept Pediat, B-3000 Louvain, Belgium
[2] Catholic Univ Louvain, Aquat Ecol Lab, B-3000 Louvain, Belgium
[3] Catholic Univ Louvain, Dept Human Genet, B-3000 Louvain, Belgium
[4] Osped Civile, I-37126 Verona, Italy
关键词
cystic fibrosis; cystic fibrosis transmembrane conductance; regulator G85E mutation; genotype-phenotype mutation;
D O I
10.1183/09031936.04.00014804
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
In this European study, the phenotype in 68 patients, homozygous or compound heterozygous for the G85E mutation, was investigated. Each index case was compared with two cystic fibrosis (CF) patients from the same clinic, matched for age and sex: one with pancreatic sufficiency (PS) and one with pancreatic insufficiency (PI). When comparing 31 G85E/F508del and F508del/F508del patients, there were no differences in median age at diagnosis, mean sweat chloride value, most recent weight for height, most recent forced expiratory volume in one second % predicted, prevalence of chronic Pseudomonas aeruginosa colonisation and typical CF complications. However, PI was less frequent in the G85E/F508del group. Comparison of 55 G85E patients (with second mutation known and not classified as mild) with PS controls (n=44) showed that the G85E patients had a significantly higher sweat chloride, more often failure to thrive at diagnosis, higher prevalence of PI, worse current weight for height, higher prevalence of chronic P. aeruginosa colonisation and liver cirrhosis. Pulse-chase experiments revealed that G85E cystic fibrosis transmembrane conductance regulator failed to mature on a M470 as well as on a V470 background. Therefore, G85E is a class II mutation. Although there is variability in its clinical presentation, G85E mutation results in a severe phenotype.
引用
收藏
页码:679 / 684
页数:6
相关论文
共 29 条
[1]  
[Anonymous], 1987, Am Rev Respir Dis, V136, P1285
[2]  
BORGO G, 1993, CLIN GENET, V44, P48
[3]   A CYSTIC-FIBROSIS PATIENT WHO IS HOMOZYGOUS FOR THE G85E MUTATION HAS VERY MILD DISEASE [J].
CHALKLEY, G ;
HARRIS, A .
JOURNAL OF MEDICAL GENETICS, 1991, 28 (12) :875-877
[4]   Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis [J].
Corey, M ;
Edwards, L ;
Levison, H ;
Knowles, M .
JOURNAL OF PEDIATRICS, 1997, 131 (06) :809-814
[5]   FAMILIAL CONCORDANCE OF PANCREATIC FUNCTION IN CYSTIC-FIBROSIS [J].
COREY, M ;
DURIE, P ;
MOORE, D ;
FORSTNER, G ;
LEVISON, H .
JOURNAL OF PEDIATRICS, 1989, 115 (02) :274-277
[6]   Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes - The polymorphic (TG)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation [J].
Cuppens, H ;
Lin, W ;
Jaspers, M ;
Costes, B ;
Teng, H ;
Vankeerberghen, A ;
Jorissen, M ;
Droogmans, G ;
Reynaert, I ;
Goossens, M ;
Nilius, B ;
Cassiman, JJ .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (02) :487-496
[7]  
CUTTING G., 2000, CYSTIC FIBROSIS, P49
[8]  
DEBRAEKELEER M, 1995, CLIN GENET, V47, P110
[9]   Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis:: a European consensus [J].
Döring, G ;
Conway, SP ;
Heijerman, HGM ;
Hodson, ME ;
Hoiby, N ;
Smyth, A ;
Touw, DJ .
EUROPEAN RESPIRATORY JOURNAL, 2000, 16 (04) :749-767
[10]  
DURIE P, 2002, PED PULMOLOLOGY S, V24, P35